Unity Biotechnology, Inc. UBX Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17
Operating expenses:
Research and development
73,717	70,957	69,081	65,657	62,387	58,907	54,167	49,413	43,428	37,373	0	0	0
General and administrative
21,522	20,046	19,467	18,164	17,036	16,016	14,266	12,361	11,004	9,617	0	0	0
Change in fair value of contingent consideration
-328	-1,352	-693	2,180	0	-	0	0	-	-	-	-	-
Impairment of long-lived assets
0	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
97,070	89,651	89,369	86,392	82,720	79,465	70,826	63,532	54,432	46,990	0	0	0
Loss from operations
-97,070	-89,651	-89,369	-86,392	-82,720	-79,465	-69,444	-62,150	-53,050	-45,608	0	0	0
Interest income
2,810	3,289	3,728	4,040	3,966	3,312	2,567	1,847	1,299	1,055	0	0	0
Other expense, net
0	-	-	-	0	-	-	-	-	-	-	-	-
Other expense, net
-	-	426	351	-	-	148	126	104	-	0	0	0
Net loss
-91,448	-82,177	-86,067	-82,703	-79,032	-76,398	-67,025	-60,429	-51,855	-44,656	0	0	0
Other comprehensive loss
Unrealized gain on marketable debt securities, net of tax
354	185	214	190	157	9	0	0	0	-	-	-	-
Unrealized gain (loss) on marketable securities, net of tax
-	-	-	-	-	-	-	-	-	-	0	0	-
Comprehensive loss
-91,094	-81,992	-85,853	-82,513	-78,875	-76,389	-67,142	-60,488	-51,993	-44,760	0	0	0
Net loss per share, basic and diluted
-0.59	-0.37	-0.51	-0.56	-0.44	3.20	-0.45	-0.76	-4.69	-3.82	-3.63	-3.62	-2.90
Weighted average number of shares used in computing net loss per share, basic and diluted
47,544	46,899	42,965	42,442	42,190	42,285	41,057	26,298	3,437	3,319	3,236	3,154	3,079